Preclinical development of ZED8, an 89Zr immuno-PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy.

Background: ZED8 is a novel monovalent antibody labeled with zirconium-89 for the molecular imaging of CD8. This work describes nonclinical studies performed in part to provide rationale for and to inform expectations in the early clinical development of ZED8, such as in the studies outlined in clin...

Descripción completa

Detalles Bibliográficos

Publicado en:	European Journal of Nuclear Medicine & Molecular Imaging Vol. 50; no. 2; pp. 287 - 302
Autores principales:	Ogasawara, Annie, Kiefer, James R., Gill, Herman, Chiang, Eugene, Sriraman, Shravan, Ferl, Gregory Z., Ziai, James, Bohorquez, Sandra Sanabria, Guelman, Sebastian, Wang, Xiangdan, Yang, Jihong, Phan, Minh Michael, Nguyen, Van, Chung, Shan, Yu, Christine, Tinianow, Jeff, Waaijer, Stijn Jan Hein, De Crespigny, Alex, Marik, Jan, Boswell, C. Andrew
Formato:	Journal Article
Publicado:	Springer Nature Jan2023
Acceso en línea:	Ver este registro en EBSCOhost